Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer Journal Article


Authors: Taunk, N. K.; Rimner, A.; Culligan, M.; Friedberg, J. S.; Brahmer, J.; Chaft, J.
Article Title: Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Abstract: Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality. Although a significant proportion of patients can be cured with surgery, with or without adjuvant or neoadjuvant chemotherapy and radiation, a significant proportion of patients will fail, particularly distantly. Over fifty percent of patients present with stage IV disease. There are multiple forms of immunotherapy available including T-cell transfer, cytokine therapy, and oncolytic viruses. Checkpoint inhibitors have shown tremendous activity in NSCLC and are currently under intense study given promising data on response. Immunotherapy and radiation therapy (RT) both show significant immune editing activity in NSCLC that may allow the innate and adaptive immune system to help control systemic disease by both radiosensitization and a sustained systemic immune response. Multiple clinical trials are underway exploring the role of adjuvant or neoadjuvant immunotherapy in operable NSCLC. A substantial amount of progress is to be made in terms of optimizing radiation dose and fractionation, immunotherapy type and dose, and integrating both to best realize the benefits of immunotherapy and radiation in operable lung cancer. © Translational lung cancer research. All rights reserved.
Keywords: immunotherapy; non-small cell lung cancer (nsclc); radiation therapy (rt)
Journal Title: Translational Lung Cancer Research
Volume: 6
Issue: 2
ISSN: 2218-6751
Publisher: Translational Lung Cancer Research  
Date Published: 2017-04-01
Start Page: 178
End Page: 185
Language: English
DOI: 10.21037/tlcr.2017.03.05
PROVIDER: scopus
PMCID: PMC5420541
PUBMED: 28529900
DOI/URL:
Notes: Review -- Export Date: 2 June 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jamie Erin Chaft
    289 Chaft
  2. Andreas Rimner
    524 Rimner
  3. Neil Taunk
    31 Taunk